Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in the development of bacterial vector technology.

Sims K Kochi1, Kevin P Killeen, Una S Ryan

  • 1Avant Immunotherapeutics, Inc., Needham, MA 02494, USA. skochi@avantimmune.com

Expert Review of Vaccines
|August 7, 2003
PubMed
Summary

Researchers are exploring live, attenuated bacteria as novel vaccine vectors for infectious diseases, cancer, and bioterrorism. These bacterial vaccines offer unique antigen delivery for enhanced immune responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progress in the development of an Advax-adjuvanted protein capsular matrix vaccine against typhoid fever.

Microbes & immunity·2025
Same author

A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.

Vaccine·2022
Same author

Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.

Vaccine·2020
Same author

A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.

PLoS neglected tropical diseases·2020
Same author

In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.

Human vaccines & immunotherapeutics·2019
Same author

Matrivax profile.

Human vaccines & immunotherapeutics·2017

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • The demand for effective vaccines against infectious diseases, cancer, bioterrorism, and food safety threats is ongoing.
  • Traditional vaccine approaches face limitations, driving the need for innovative strategies.
  • Live, attenuated bacteria expressing foreign antigens are emerging as promising vaccine candidates.

Purpose of the Study:

  • To review the development and application of live, attenuated bacterial vectors for vaccine purposes.
  • To highlight the potential of various bacterial species as vaccine delivery systems.
  • To discuss the advantages of bacterial vector vaccines in traditional and non-traditional therapeutic areas.

Main Methods:

  • Review of existing literature on bacterial vector vaccine research.

Related Experiment Videos

  • Analysis of studies focusing on attenuated bacterial strains like Salmonella, Shigella, Listeria monocytogenes, Mycobacterium bovis-BCG, and Vibrio cholerae.
  • Evaluation of antigen delivery and immune presentation capabilities of different bacterial vectors.

    • Main Results:

    • Salmonella strains have been extensively studied as bacterial vaccine vectors.
    • Other bacteria such as Shigella, Listeria monocytogenes, Mycobacterium bovis-BCG, and Vibrio cholerae show promise as alternative vectors.
    • These vectors offer unique mechanisms for antigen delivery and immune stimulation.

    Conclusions:

    • Live, attenuated bacterial vectors represent a significant advancement in vaccine development.
    • Diverse bacterial species provide versatile platforms for creating vaccines against a range of diseases.
    • Further research into these bacterial vaccine systems holds potential for addressing global health challenges.